Notice of Results
27 juil. 2016 04h00 HE
|
AstraZeneca PLC
AstraZeneca PLC H1 2016 Results
Tomorrow, Thursday 28 July 2016, AstraZeneca PLC will publish its H1 2016
results at 07:00 UK time.
An analyst presentation will take place at 12:00 UK time and will...
QTERN (saxa/dapa) EU approved for type-2 diabetes
19 juil. 2016 09h29 HE
|
AstraZeneca PLC
This announcement contains inside information
19 July 2016 14:15
ASTRAZENECA RECEIVES APPROVAL IN THE EU FOR QTERN (SAXAGLIPTIN AND
DAPAGLIFLOZIN) FOR TREATMENT OF TYPE 2 DIABETES
AstraZeneca...
ASTRAZENECA PLC ANNOUNCES TAGRISSO MET PRIMARY ENDPOINT IN PHASE III 2ND-LINE LUNG CANCER TRIAL
18 juil. 2016 02h00 HE
|
AstraZeneca PLC
Tagrisso demonstrated superior progression-free survival compared to standard
platinum-based chemotherapy, with a safety profile consistent with previous
trials
First randomised trial to evaluate the...
AZ resolves Faslodex patent litigation in the US
13 juil. 2016 02h00 HE
|
AstraZeneca PLC
This announcement contains inside information
13 July 2016 07:00
ASTRAZENECA ENTERS INTO AGREEMENT TO RESOLVE FASLODEX PATENT LITIGATION IN THE
US
AstraZeneca today announced that it has entered...
AZ enters licensing agreements with LEO Pharma
01 juil. 2016 02h00 HE
|
AstraZeneca PLC
ASTRAZENECA ENTERS LICENSING AGREEMENTS WITH LEO PHARMA IN SKIN DISEASES
Agreement for development and commercialisation of tralokinumab for atopic
dermatitis supports sharper focus on main therapy...
ASTRAZENECA PLC ANNOUNCES NEW ANTIBIOTIC ZAVICEFTA APPROVED IN THE EUROPEAN UNION FOR PATIENTS WITH SERIOUS BACTERIAL INFECTIONS
28 juin 2016 02h00 HE
|
AstraZeneca PLC
28 June 2016
AstraZeneca today announced that the European Commission (EC) has granted
marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known
as CAZ AVI), a new combination...
ASTRAZENECA PROVIDES UPDATE ON FLUMIST QUADRIVALENT VACCINE IN THE US FOR THE 2016-17 INFLUENZA SEASON
23 juin 2016 02h00 HE
|
AstraZeneca PLC
AstraZeneca today confirmed that the Advisory Committee on Immunization
Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has
provided its interim recommendation on the use of...
Director/PDMR Shareholding
14 juin 2016 10h00 HE
|
AstraZeneca PLC
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 13 June 2016, the interest of Pascal Soriot, a person discharging managerial
responsibilities, in the...
AZ agreement with Aspen for anaesthetics portfolio
09 juin 2016 02h26 HE
|
AstraZeneca PLC
ASTRAZENECA ENTERS COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETIC
MEDICINES PORTFOLIO
Agreement expands commercial reach for anaesthetics and supports the Company's
sharp focus on innovative...
ASTRAZENECA COMPLETES US LICENSING AGREEMENT WITH IRONWOOD PHARMACEUTICALS FOR LESINURAD
03 juin 2016 02h00 HE
|
AstraZeneca PLC
AstraZeneca today announced that it has completed the...